Published on 10 May 2023 on Benzinga via Yahoo Finance
Ensysce Biosciences Inc (NASDAQ: ENSC) completed PF614-MPAR-101, a clinical study examining the company's first pain medication with overdose protection, PF614-MPAR.
The final Part B of the study examined dose escalation of PF614-MPAR from 25 to 200 mg (1 to 8 dose units) and showed that PF614-MPAR reduced opioid delivery when three or more doses were consumed simultaneously.